Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer.
Qie Y, Huang S, Shen C, Wu Z, Da L, Jia K, Zhang Z, Zhao G, Wang L, Xu G, Zhao Y, Liang R, Guo J, Li C, Dong H, Li M, Li H, Chen H, Tian D, Wu C, Zhang W, An Z, Wang H, Niu Y, Hu H.
Qie Y, et al. Among authors: zhao g.
Clin Cancer Res. 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39777450